Jove
Visualize
Contáctanos
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Videos de Conceptos Relacionados

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

169
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
169
Ultrasound II: Endoscopic Ultrasound and FibroScan01:25

Ultrasound II: Endoscopic Ultrasound and FibroScan

499
Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):
499
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

200
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
200
Synthesis and Regulation of Thyroid Hormones01:20

Synthesis and Regulation of Thyroid Hormones

7.1K
Low blood levels of the thyroid hormones — triiodothyronine (T3) and thyroxine (T4) — signal the hypothalamus to release the thyrotropin-releasing hormone (TRH). TRH then reaches the pituitary gland and stimulates the release of thyroid-stimulating hormone(TSH) into the bloodstream.
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The...
7.1K
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

236
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
236
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

1.8K
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
1.8K

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

Evaluation of Serum GPR-120 Levels in Diabetic Patients With and Without Nephropathy: A Comparative Study on Lipid and Renal Parameters.

Cureus·2025
Same author

Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor (rhu GM-CSF) as Adjuvant Therapy for Invasive Fungal Diseases.

Open forum infectious diseases·2022
Same author

Colonoscopy surveillance following adenoma removal to reduce the risk of colorectal cancer: a retrospective cohort study.

Health technology assessment (Winchester, England)·2022
Same author

Colorectal cancer risk following polypectomy in a multicentre, retrospective, cohort study: an evaluation of the 2020 UK post-polypectomy surveillance guidelines.

Gut·2021
Same author

A Case of Linear IgA Bullous Dermatosis Successfully Treated with Omalizumab.

Indian journal of dermatology·2021
Same author

Psychosocial and Financial Impact of Disease among Patients of Dermatophytosis, a Questionnaire-Based Observational Study.

Indian dermatology online journal·2020

Video Experimental Relacionado

Updated: Jan 8, 2026

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution
04:14

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution

Published on: April 16, 2019

12.5K

Disfunción tiroidea en la enfermedad del hígado graso no alcohólico: un estudio de casos y controles

Harshit Malkan1, Bhavita Patel2, Mahesh G Solu1

  • 1Department of General Medicine, Dr. Kiran C Patel Medical College and Research Institute, Bharuch, Gujarat, India.

Bioinformation
|December 15, 2025
PubMed
Resumen

La disfunción tiroidea es común en la enfermedad del hígado graso no alcohólico (NAFLD). El empeoramiento de la función tiroidea se correlaciona con la gravedad de NAFLD, lo que indica la necesidad de un cribado tiroideo en pacientes con NAFLD.

Palabras clave:
Disfunción metabólicaenfermedad del hígado graso no alcohólico (NAFLD)disfunción tiroidea

Más Videos Relacionados

Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss
07:03

Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss

Published on: July 19, 2024

1.6K
Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis
06:26

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis

Published on: July 18, 2025

645

Videos de Experimentos Relacionados

Last Updated: Jan 8, 2026

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution
04:14

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution

Published on: April 16, 2019

12.5K
Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss
07:03

Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss

Published on: July 19, 2024

1.6K
Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis
06:26

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis

Published on: July 18, 2025

645

Área de la Ciencia:

  • Endocrinología
  • Hepatología
  • Síndrome Metabólico

Sus antecedentes:

  • La enfermedad del hígado graso no alcohólico (NAFLD) es una consecuencia hepática de la disfunción metabólica.
  • La investigación emergente sugiere una conexión entre NAFLD y anomalías tiroideas.

Objetivo del estudio:

  • Investigar la prevalencia de la disfunción tiroidea en pacientes con NAFLD.
  • Explorar la asociación entre la gravedad de NAFLD y la función tiroidea.

Principales métodos:

  • Un estudio de casos y controles que involucró a 120 participantes adultos.
  • Evaluación de la función tiroidea (hipotiroidismo manifiesto y subclínico) en relación con el estado y la gravedad de NAFLD.

Principales resultados:

  • La disfunción tiroidea fue más prevalente en los casos de NAFLD en comparación con los controles.
  • El hipotiroidismo manifiesto afectó al 20% y el hipotiroidismo subclínico al 5% de los pacientes con NAFLD.
  • Se observó una correlación significativa entre el aumento de la gravedad de NAFLD y tasas más altas de hipotiroidismo manifiesto (66,7% en casos de Grado 3).

Conclusiones:

  • Existe una fuerte asociación entre la alteración de la función tiroidea y la gravedad de NAFLD.
  • Se recomienda el cribado tiroideo rutinario para las personas diagnosticadas con NAFLD para ayudar en el manejo integral.